ARTICLE | Clinical News
DnaJP1: Phase II data
November 7, 2005 8:00 AM UTC
In a double-blind, placebo-controlled, U.S. Phase II trial in 160 patients, AT-001 missed the primary endpoint of AUC of ACR20 response rates at days 112, 140 and 168 (p=0.099). A post hoc analysis sh...